A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Nexvax2 Preceded by a Dose Titration Period in Subjects With Celiac Disease Currently on a Gluten-Free Diet
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2017
At a glance
- Drugs HLA DQ2 peptide vaccine (Primary)
- Indications Coeliac disease
- Focus Adverse reactions
- Sponsors ImmusanT
- 22 Feb 2017 Results of this trial supports a dosing regimen for a Phase II trial (see profile 258610), according to a ImmusanT media release.
- 22 Feb 2017 Status changed from active, no longer recruiting to completed, as reported in an ImmusanT media release.
- 07 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2017.